CA2098029C - Particules de type retrovirus contenant des glycoproteines d'enveloppe modifiees - Google Patents

Particules de type retrovirus contenant des glycoproteines d'enveloppe modifiees Download PDF

Info

Publication number
CA2098029C
CA2098029C CA 2098029 CA2098029A CA2098029C CA 2098029 C CA2098029 C CA 2098029C CA 2098029 CA2098029 CA 2098029 CA 2098029 A CA2098029 A CA 2098029A CA 2098029 C CA2098029 C CA 2098029C
Authority
CA
Canada
Prior art keywords
amino acid
hiv
acid sequence
particle
retrovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA 2098029
Other languages
English (en)
Other versions
CA2098029A1 (fr
Inventor
Benjamin Rovinski
Joel Haynes
Shi Xian Cao
Michel Henri Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Connaught Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Connaught Laboratories Ltd filed Critical Connaught Laboratories Ltd
Priority to CA 2098029 priority Critical patent/CA2098029C/fr
Publication of CA2098029A1 publication Critical patent/CA2098029A1/fr
Application granted granted Critical
Publication of CA2098029C publication Critical patent/CA2098029C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA 2098029 1993-06-09 1993-06-09 Particules de type retrovirus contenant des glycoproteines d'enveloppe modifiees Expired - Lifetime CA2098029C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2098029 CA2098029C (fr) 1993-06-09 1993-06-09 Particules de type retrovirus contenant des glycoproteines d'enveloppe modifiees

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2098029 CA2098029C (fr) 1993-06-09 1993-06-09 Particules de type retrovirus contenant des glycoproteines d'enveloppe modifiees

Publications (2)

Publication Number Publication Date
CA2098029A1 CA2098029A1 (fr) 1994-12-10
CA2098029C true CA2098029C (fr) 2000-10-03

Family

ID=4151769

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2098029 Expired - Lifetime CA2098029C (fr) 1993-06-09 1993-06-09 Particules de type retrovirus contenant des glycoproteines d'enveloppe modifiees

Country Status (1)

Country Link
CA (1) CA2098029C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1185811A (zh) * 1995-03-31 1998-06-24 H·沃尔夫 依赖于逆转录病毒样颗粒的抗原呈递系统

Also Published As

Publication number Publication date
CA2098029A1 (fr) 1994-12-10

Similar Documents

Publication Publication Date Title
US7008784B1 (en) Non-infectious, non-replicating, immunogenic human immunodeficiency virus-like particles
Griffiths et al. Hybrid human immunodeficiency virus Gag particles as an antigen carrier system: induction of cytotoxic T-cell and humoral responses by a Gag: V3 fusion
US5866137A (en) Self-assembled, non-infectious, non-replicating; immunogenic retrovirus-like particles comprising modified HIV genomes devoid of long terminal repeats and chimeric envelope glycoproteins
US5866320A (en) Nucleic acids encoding for non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
US7229625B2 (en) Retrovirus-like particles made non-infectious by a plurality of mutations
JP6165612B2 (ja) コンセンサス／先祖免疫原
Girard et al. Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1
US5714374A (en) Chimeric rhinoviruses
CA2331599C (fr) Vaccin de vih a deficience de replication
Cho et al. Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous simian/human immunodeficiency virus infection in pigtailed macaques
Rovinski et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine
Buonaguro et al. High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A
Chakrabarti et al. Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate
Berzofsky Development of artificial vaccines against HIV using defined epitopes
EP1038001B1 (fr) Expression constitutive de particules non infectieuses du type hiv
Corbet et al. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons
CA2098029C (fr) Particules de type retrovirus contenant des glycoproteines d'enveloppe modifiees
EP0276591B1 (fr) Vaccin constitué par un vecteur viral et ADN recombinant codant notamment pour la protéine p25 du virus agent causal du S.I.D.A.
Cranage et al. The simian immunodeficiency virus transmembrane protein is poorly immunogenic in inactivated virus vaccine
Griffiths Analysis of antigen presentation using particulate carrier systems

Legal Events

Date Code Title Description
EEER Examination request